Clinical Trials Directory

Trials / Completed

CompletedNCT01733030

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.

Status
Completed
Phase
Study type
Observational
Enrollment
56 (actual)
Sponsor
University of Minnesota · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

PROJECT SUMMARY: PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.

Detailed description

To fullfill the objectives of this application, a generalization paradigm has been designed and psychophysiologically validated in which 6 rings presented on a computer screen gradually increase in size. For half of participants the smallest ring is the conditioned stimulus paired with electric shock (CS+) and the largest is the unpaired stimulus (CS-), and for the other half of participants this is reversed. Activity in fear-related brain structures measured via fMRI are predicted to gradually decrease as the presented stimulus gradually becomes less similar to the CS+, forming a generalization slope or gradient. One central hypothesis of the current application is that DCS (Seromycin) will dose dependently increase the steepness of generalization gradients (i.e., reduce fear generalization). This study will include 3 groups of healthy adults recieving either 1) 500 mg Seromycin, 2) 250 mg Seromycin, or placebo only prior to acquisition of fear conditioning. Twenty four hours later, participants will return to complete an fMRI during which brain responses to the danger cue and stimuli resembling the danger cue will be assessed.

Conditions

Interventions

TypeNameDescription
DRUGSeromycin250 mg versus 500 mg versus placebo effects on conditioned fear generalization
DRUGSeromycin

Timeline

Start date
2013-01-01
Primary completion
2015-10-01
Completion
2015-10-01
First posted
2012-11-26
Last updated
2017-05-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01733030. Inclusion in this directory is not an endorsement.